Please login to the form below
J&J profit falls on recall woes
Johnson & Johnson has reported a 23 per cent decline in profit for Q1 2011 in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuit
Johnson & Johnson (J&J) has reported a 23 per cent decline in profit for the first quarter in spite of increased revenues, as the company experienced high costs related to product recalls and lawsuits.
The company's revenue rose 3.5 per cent to $16.17bn for the quarter. Net income was $3.48bn, or $1.25 per share, down from $4.53bn, or $1.62 per share, in 2010's first quarter, when results were positively affected by a $910m gain related to litigation.
Consumer product sales were down 2.2 per cent to $3.68bn, largely due to the recalls. Prescription drug revenue was up 7.5 per cent globally to $6.1bn, while revenue from medical devices and diagnostics rose 3.3 per cent, to $6.43bn.
"Our pharmaceuticals business demonstrated strong operational sales growth this quarter of over 6 per cent, due to the success of our recently launched products such as Stelara and Simponi and core medicines such Remicade and Prezista," J&J chief financial officer Dominic Caruso said during a conference call.
"And our consumer healthcare business saw sequential improvements in its operational sales growth versus the fourth quarter of 2010 in various markets, excluding the impact of the plant shutdown and the lower production levels in our McNeil US over-the-counter (OTC) business, where we are making good progress in addressing the manufacturing and quality issues in that business," he added.
J&J also increased its estimate of costs per share related to recalls this year. "We had previously included in our guidance for 2011 an impact of approximately $0.06 per share from of the ongoing remediation efforts at McNeil," Caruso said.
"Now that we have finalised the terms of the Consent Decree, we estimate that, that impact will be twice that amount. This results from both the slowdown in sales reflecting the impact on production volumes as we implement the additional quality steps outlined in the Decree, as well as additional investments required in the remediation process."
J&J raised its profit forecast for the year by 10 cents to $4.90 to $5 per share.
Share
Related Hub content
Subscribe to our email news alerts
- Novo Nordisk and Valo Health agree deal worth up to $3.3bn
- Landscape review reveals £1.1bn of UK funding for rare diseases
- Cancer Research UK partners with French cancer institute
- New diagnosis pathway has been launched to mark European Myeloma Day
- Impacting Lives with Rare Disease Education
- Sandoz biosimilar receives EC approval to treat MS
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
